Botulinum toxin for conditions of the female pelvis.
Int Urogynecol J
; 24(7): 1073-81, 2013 Jul.
Article
em En
| MEDLINE
| ID: mdl-23344218
ABSTRACT
INTRODUCTION AND HYPOTHESIS:
Botulinum toxin has recently been approved by the Food and Drug Administration (FDA) for the treatment of urinary incontinence associated with neurogenic detrusor overactivity. However, it has also been used off-label for a multitude of other conditions in the female pelvis, including urological, gynecological, and colorectal. This article reviews the most recent data regarding its efficacy and safety, and administration techniques for those conditions.METHODS:
A literature review of the most relevant reports published between 1985 and 2012.RESULTS:
Urinary incontinence related to neurogenic detrusor overactivity is currently the only approved indication in the female pelvis. Other supported off-label uses include idiopathic detrusor overactivity, interstitial cystitis/bladder pain syndrome, detrusor sphincter dyssynergia, high-tone pelvic floor dysfunction, anal fissure, anismus, and functional anal pain.CONCLUSIONS:
Botulinum toxin may effectively and safely be used in many conditions of the female pelvis. More high quality research is needed to better clarify its role in the therapeutic algorithm for those indications.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doenças do Ânus
/
Doenças da Bexiga Urinária
/
Toxinas Botulínicas
/
Antidiscinéticos
/
Distúrbios do Assoalho Pélvico
Limite:
Female
/
Humans
Idioma:
En
Revista:
Int Urogynecol J
Assunto da revista:
GINECOLOGIA
/
UROLOGIA
Ano de publicação:
2013
Tipo de documento:
Article
País de afiliação:
Estados Unidos